تداخل‌های دارویی
Concizumab + Factor viii
شدت: شدید
Concizumab and Factor viii: major interaction.
آخرین به‌روزرسانی
ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصه‌ای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمی‌شود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.
محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.
خلاصه
Concizumab reduces bleeding by inhibiting tissue factor pathway inhibitor, so added factor VIII at high or frequent doses can increase thrombotic risk. Thromboembolic events have been reported with concomitant breakthrough-bleed treatment.
معنای این تداخل به زبان ساده
Concizumab and Factor viii can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Concizumab belongs to Miscellaneous; Factor viii belongs to Cardiovascular.
چرا رخ می‌دهد
Additive procoagulant effects of TFPI inhibition and exogenous factor replacement.
اقدام لازم
Treat breakthrough bleeds with the lowest approved factor VIII dose that achieves hemostasis. Monitor for signs of thrombosis.
از داروساز چه بپرسید
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
ویژه اعضای Pro+
باز کردن کل صفحه
یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا توصیه‌های کامل مدیریت Concizumab و Factor viii، یادداشت‌های تکمیلی، جزئیات شواهد و بررسی‌کننده تداخل برای کل نسخه را باز کنید.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Pro+ را ۱۴ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.
تداخلات دیگر Concizumab
تداخلات دیگر Factor viii
پرسش‌های متداول
Can I take Concizumab with Factor viii?
MediHelp rates the interaction as major. Concizumab and Factor viii can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Concizumab reduces bleeding by inhibiting tissue factor pathway inhibitor, so added factor VIII at high or frequent doses can increase thrombotic risk. Thromboembolic events have been reported with concomitant breakthrough-bleed treatment.
How serious is the interaction between Concizumab and Factor viii?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Treat breakthrough bleeds with the lowest approved factor VIII dose that achieves hemostasis. Monitor for signs of thrombosis.
What other medicines interact with Concizumab?
MediHelp also lists interactions of Concizumab with, for example, Factor ix. The full list is on the Concizumab page.
تک‌نگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp
مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.
